Peptides-based therapeutics: Emerging potential therapeutic agents for COVID-19

Shah, Jagat Narayan; Guo, Guang-Qin; Anand, Krishnan; Ramesh, Muthusamy; Katari, Naresh Kumar; Shahbaaz, Mohd; Abdellattif, Magda H.; Singh, Sachin Kumar; Dua, Kamal

doi:10.1016/j.therap.2021.09.007

Cited by 20 publications

(15 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Current research into drugs to treat COVID-19 includes peptides, antibodies, natural products, drug repurposing, as well as the synthesis of new molecules. 32 , 33 , 34 In drug discovery programs, small molecules as therapeutics agents have an important role because of economic limitations. Various small molecules are reported as inhibitors of SARS-CoV-2 entry [i.e., of S proteins (S1/S2/RBD) and ACE2 (RBD/ACE2 interface)].…”

Section: Mutations In the Target Site Of The S Pro...mentioning

confidence: 99%

Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein

Verma

Patil²,

Gupta

2022

Drug Discovery Today

View full text Add to dashboard Cite

Section: Mutations In the Target Site Of The S Pro...mentioning

confidence: 99%

Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein

Verma

Patil²,

Gupta

2022

Drug Discovery Today

View full text Add to dashboard Cite

“…Various peptide‐based compounds with an antiviral function such as lactoferrin and other antibacterial peptides are likely proinhibitors of SARS‐CoV‐2 disease (Chang et al, 2020; Shah et al, 2021). Among these peptide‐based materials, bacteriocins secretion by probiotics have a bactericidal or bacteriostatic effect against related or unrelated bacteria possibly for inhibition against numerous viruses.…”

Section: The Possible Biological Role Of Postbiotics In Inhibition Of...mentioning

confidence: 99%

Postbiotics as potential promising tools for SARS-CoV-2 disease adjuvant therapy

Khani

Soleimani

Noorkhajavi

et al. 2022

Journal of Applied Microbiology

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic defines the global health tension of our time. There are several continuous efforts to find a definitive cure in this regard. According to some adverse effects and problems of customary SARS-CoV-2 disease therapies, bioactive compounds, for example probiotics-derived metabolites (postbiotics) have been accomplishing supreme importance by investigators for adjuvant cures in patients with SARS-CoV-2. Postbiotics inhibit angiotensin-converting enzyme 2 activity and stimulate the immune system. They also boost the SARS-CoV-2 disease treatment effectiveness and reduce its adverse effects in SARS-CoV-2 illness patients as a result of antiviral and anti-inflammatory effects. Furthermore, postbiotics having unique features such as high safety, high shelf life and stability to the gastrointestinal tract can be utilized as hopeful instruments for both adjuvant and inhibition strategies in SARS-CoV-2 patients with no earnest unfavourable adverse effects. The concept of postbiotics and their biocompatible characteristics are comprehensively discussed in the present review while highlighting the bilateral relationship between postbiotic biometabolites and respiratory tract infection with a special look at the potential biological role in the inactivation of SARS-CoV-2 and reduction of related inflammatory pathways.

show abstract

“…Thus, new technologies/strategies for the rapid development of therapeutics of novel protein pathogens targets are needed for an effective response to future pandemics ( Pardi and Weissman, 2020 ). Among the two emerging promiscuous approaches, which may significantly reduce the time to develop new treatments in case of novel pathogens, are the drug repurposing approach ( Pushpakom et al, 2019 ) and peptide-based therapeutics mainly targeting protein-protein interactions ( Shah et al, 2022 ; Sharma et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

“…One of the extensively explored targets to develop COVID-19 specific drug(s) ( Shah et al, 2022 ) is an interaction between the receptor-binding domain (RBD) of the virus’ spike (S) glycoprotein ( Wrapp et al, 2020 ) and human receptor angiotensin-converting enzyme 2 (ACE2) ( Walls et al, 2020 ). This protein-protein recognition process is involved in the early stages of the SARS-CoV-2 life cycle leading to the host cell membrane penetration and finally the virus replication ( Yan et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

“…The protein-protein recognition process between the receptor-binding domain (RBD) of the virus’ spike (S) glycoprotein and human receptor angiotensin-converting enzyme 2 (ACE2) is involved in the early stages of the SARS-CoV-2 life cycle leading to the host cell membrane fusion and finally the virus replication ( Walls et al, 2020 ). Immediately after the outbreak of SARS-CoV-2, the endeavor to develop a new targeted therapy against novel coronavirus was started, and one of the extensively explored drug targets in the scientific literature is the mentioned virus-host protein-protein interaction ( Ghosh and Weinberg, 2021 ; Shah et al, 2022 ; Sharma et al, 2022 ). Many peptides with similar properties were proposed by other groups using different strategies based on natural or synthetic peptide libraries or even similar to our approach based on different, native parts of h ACE2 ( Baig et al, 2020 ; Barh et al, 2020 ; Chatterjee et al, 2020 ; Chaturvedi et al, 2020 ; Han and Král, 2020 ; Huang et al, 2020 ; Jaiswal and Kumar, 2020 ; Sitthiyotha and Chunsrivirot, 2020 ; Zhao et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Improvement of native structure-based peptides as efficient inhibitors of protein-protein interactions of SARS-CoV-2 spike protein and human ACE2

Odolczyk

Klim²,

Podsiadła-Białoskórska³

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

New pathogens responsible for novel human disease outbreaks in the last two decades are mainly the respiratory system viruses. Not different was the last pandemic episode, caused by infection of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One of the extensively explored targets, in the recent scientific literature, as a possible way for rapid development of COVID-19 specific drug(s) is the interaction between the receptor-binding domain of the virus’ spike (S) glycoprotein and human receptor angiotensin-converting enzyme 2 (hACE2). This protein-protein recognition process is involved in the early stages of the SARS-CoV-2 life cycle leading to the host cell membrane penetration. Thus, disrupting this interaction may block or significantly reduce the infection caused by the novel pathogen. Previously we have designed (by in silico structure-based analysis) three very short peptides having sequences inspirited by hACE2 native fragments, which effectively bind to the SARS-CoV-2 S protein and block its interaction with the human receptor. In continuation of the above mentioned studies, here we presented an application of molecular modeling approach resulting in improved binding affinity of the previously proposed ligand and its enhanced ability to inhibit meaningful host-virus protein-protein interaction. The new optimized hexapeptide binds to the virus protein with affinity one magnitude higher than the initial ligand and, as a very short peptide, has also great potential for further drug development. The peptide-based strategy is rapid and cost-effective for developing and optimizing efficient protein-protein interactions disruptors and may be successfully applied to discover antiviral candidates against other future emerging human viral infections.

show abstract

Peptides-based therapeutics: Emerging potential therapeutic agents for COVID-19

Cited by 20 publications

References 59 publications

Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein

Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein

Postbiotics as potential promising tools for SARS-CoV-2 disease adjuvant therapy

Improvement of native structure-based peptides as efficient inhibitors of protein-protein interactions of SARS-CoV-2 spike protein and human ACE2

Contact Info

Product

Resources

About